The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Horizon Discovery Group Plc

11 Dec 2020 17:32

GFGW LLC - Form 8.3 - Horizon Discovery Group Plc

GFGW LLC - Form 8.3 - Horizon Discovery Group Plc

PR Newswire

London, December 11

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:GF GW, LLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.· Glick Family Gold Mountain Trust & Pluchenik Family Gold Mountain Trust (trustee, settlor and beneficiaries for both trusts are: Pax PT Company LLC, Louis Glick and Issue of Louis Glick, respectively.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeHorizon Discovery Group Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure9/12/2020
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:1p ordinary share
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:2,239,9111.41%
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:2,239,9111.41%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
1p ordinaryPurchase30,217186p
1p ordinaryPurchase647,299186.5p
1p ordinaryPurchase62,395187p

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:December 9, 2020
Contact name:Shmuel Lieberman
Telephone number*:212.259.0375

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
26th Jan 20187:00 amRNSBlock Listing Six Monthly Return
18th Dec 20177:00 amRNSAgreement with Roche Diagnostics
5th Dec 20177:00 amRNSHZD expand CRISPR license rights with ERS Genomics
24th Nov 20172:54 pmRNSTotal Voting Rights
3rd Oct 20172:10 pmRNSTotal Voting Rights
26th Sep 20177:00 amRNSInterim Results
25th Sep 20173:35 pmRNSHoldings in Company
8th Sep 20177:00 amRNSTrading Update
4th Sep 20173:42 pmRNSHolding(s) in Company
4th Sep 20172:37 pmRNSHolding(s) in Company
31st Aug 20173:30 pmRNSCompletion of Acquisition
24th Aug 20173:56 pmRNSHolding(s) in Company
24th Aug 20173:29 pmRNSHolding(s) in Company
23rd Aug 20178:18 amRNSCompletion of Placing
22nd Aug 20172:12 pmRNSUpdate on Acquisition of GE Healthcare Dharmacon
7th Aug 201710:19 amRNSResult of General Meeting
7th Aug 20177:00 amRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSBlock Listing Application
19th Jul 20177:00 amRNSAcquisition and Proposed Placing to Raise £80m
7th Jul 20177:00 amRNSAdditional Listing
4th Jul 20171:55 pmRNSHoldings in Company
3rd Jul 20177:00 amRNSReference Standards support successful FDA filing
28th Jun 201710:57 amRNSResult of AGM
26th Jun 20171:54 pmRNSHolding(s) in Company
16th Jun 20177:00 amRNSAdditional Listing
6th Jun 20177:00 amRNSAdditional Listing
2nd Jun 20177:00 amRNSAnnual Report and Notice of Annual General Meeting
31st May 20177:00 amRNSAdditional Listing
30th May 20177:00 amRNSPreliminary Results Year Ended 31 December 2016
22nd May 20177:00 amRNSHZD Licenses New Gene Editing Technology Platform
9th May 20177:00 amRNSPerformance update in Immuno-Oncology
21st Apr 20177:00 amRNSAdditional Listing
19th Apr 20177:00 amRNSNotice of Results
11th Apr 20172:57 pmRNSHoldings in Company
7th Apr 20175:01 pmRNSGrant of Options
6th Apr 20177:00 amRNSAdditional Listing
30th Mar 20179:08 amRNSHoldings in Company
24th Mar 20177:00 amRNSAdditional Listing
23rd Mar 201711:24 amRNSHoldings in Company
20th Mar 201710:42 amRNSHoldings in Company
14th Mar 20177:00 amRNSAgreement for NIPT Reference Standards
23rd Feb 20177:00 amRNSSite Visit
20th Feb 20171:21 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSAdditional Listing
14th Feb 20177:00 amRNSMaster Service Agreement with Top 3 Pharma Company
10th Feb 20177:00 amRNSAdditional Listing
31st Jan 20173:06 pmRNSHolding(s) in Company
31st Jan 20177:00 amRNSIssue of Equity
26th Jan 20171:50 pmRNSHolding(s) in Company
24th Jan 20177:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.